Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
97 hedge funds and large institutions have $171M invested in Antares Pharma, Inc. in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 47 increasing their positions, 18 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
174% more call options, than puts
Call options by funds: $1.01M | Put options by funds: $368K
161% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 18
11% more funds holding
Funds holding: 87 → 97 (+10)
10% less capital invested
Capital invested by funds: $190M → $171M (-$18.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Harvey Capital Management
Palm Beach,
Florida
|
+$2.31M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.67M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.01M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$964K |
| 5 |
WHI
William Harris Investors
Chicago,
Illinois
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$21.1M |
| 2 |
DM
Deerfield Management
New York
|
-$3.26M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$944K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$913K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$666K |
ATRS Hedge Fund Activity: Q3 2013 in Review
97 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q3 2013, worth a combined $171M — down 9.8% from $190M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ATRS positions and 4 closed out — a net gain of 10 holders — while 47 added to existing stakes and 18 trimmed.
The largest buyer was Harvey Capital Management, opening a new position worth an estimated $2.31M. The largest seller was OrbiMed, cutting an estimated $21.1M.
- 97 institutional investors held Antares Pharma, Inc. (ATRS) as of Q3 2013, up from 87 in Q2 2013.
- Funds reported $171M of Antares Pharma, Inc. stock for Q3 2013, down 9.8% quarter-over-quarter.
- 14 funds opened new Antares Pharma, Inc. positions in Q3 2013 and 4 closed out, a net change of +10 holders.
- The largest Antares Pharma, Inc. buyer in Q3 2013 was Harvey Capital Management, an estimated $2.31M added.
- The largest Antares Pharma, Inc. seller in Q3 2013 was OrbiMed, an estimated $21.1M sold.
Based on aggregated 13F filings for Q3 2013.